MedTrace Logo

Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer

NCT00002580 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2013-11-06

No results posted yet for this study

Summary

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with hormone therapy may kill more tumor cells. It is not yet known which treatment regimen is most effective for breast cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen with that of ovarian ablation, and/or combination chemotherapy in treating premenopausal women with stage I, stage II, or stage IIIA breast cancer.

Conditions

Interventions

DRUG

cyclophosphamide

DRUG

fluorouracil

DRUG

goserelin acetate

DRUG

leuprolide acetate

DRUG

methotrexate

DRUG

tamoxifen citrate

PROCEDURE

conventional surgery

PROCEDURE

laparoscopic surgery

PROCEDURE

oophorectomy

RADIATION

radiation therapy

Sponsors & Collaborators

  • Scottish Cancer Therapy Network

    lead OTHER

Principal Investigators

  • W.D. George, MD, MS, FRCS · University of Glasgow

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1993-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002580 on ClinicalTrials.gov